KRAS G12D mutation
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-KRAS-G12D |
|---|---|
| Type | Biomarker |
| Aliases | KRAS G12DМутація KRAS G12D |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"exon": "2", "functional_impact": "activating (constitutive RAS-RAF-MEK-ERK signalling)", "gene": "KRAS", "hgvs_protein": "p.G12D", "variant_type": "missense"} |
| Measurement | MethodTumor-tissue NGS panel (preferred) OR ctDNA NGS |
| Actionability lookup | {"gene": "KRAS", "variant": "G12D"} |
| Related biomarkers | BIO-KRAS-G12C BIO-RAS-MUTATION |
Notes
~40% of PDAC, ~13% of CRC, ~6% of NSCLC adenocarcinoma. No FDA-approved selective inhibitor as of 2025 (MRTX1133, RMC-9805 in early trials). Common alongside other PDAC adverse markers (TP53, SMAD4, CDKN2A). EGFR-targeted therapy (cetuximab/panitumumab) contraindicated in RAS-mutant CRC — anti-EGFR resistance is a defining feature.
Used By
Actionability
BMA-KRAS-G12D-CRC- KRAS G12D in mCRC predicts anti-EGFR resistance. No approved targeted therapy 2026; trial...BMA-KRAS-G12D-ENDOMETRIAL- KRAS G12D in endometrial — common in endometrioid; no approved targeted therapy.BMA-KRAS-G12D-NSCLC- KRAS G12D in NSCLC (~5%) — pan-KRAS / G12D-selective inhibitors in early trials. ICI-base...BMA-KRAS-G12D-OVARIAN- KRAS G12D in mucinous/low-grade serous ovarian — no approved drug; trial-only (MRTX1133).BMA-KRAS-G12D-PDAC- KRAS G12D is the most common PDAC driver (~35-40%). MRTX1133 (Mirati/Bristol) and RMC-980...
Biomarker
BIO-GNAS- GNAS activating mutation (Gα_s protein)BIO-KRAS-G12V- KRAS G12V mutationBIO-PTPN11- PTPN11 activating mutation (SHP2)